The cost of managing GC in patients with curable disease has been estimated at $42 521 for surgery alone, compared with $156 54726,27 per QALY for human epidermal growth factor receptor type-2 (HER2)-positive metastatic disease treated with trastuzumab chemotherapy. The gene discussed is ERBB2; the disease is metastatic neoplasm.